Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Mustang Bio enters $20mm venture debt financing with Horizon, gets $15mm up front

Executive Summary

Mustang Bio Inc. (gene and cell therapies for cancers and rare genetic diseases) entered into a $20mm venture debt financing agreement with Horizon Technology Finance. The company received $15mm of the loan up front and can draw down on the remaining $5mm pending achievement of preset milestones. The loan accrues interest at a rate equal to 9% plus the amount by which the one-month LIBOR rate (as reported in the WSJ) exceeds 2.5%, and will be repaid in 42 monthly payments (18 months interest only and 24 months of principal and accrued interest). Upon the initial closing, Mustang issued Horizon ten-year warrants to purchase 288k common shares at $3.47.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Private Placement

Related Companies